{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-090855","form_type":"8-K/A","ticker":null,"cik":"0001780097","company_name":"Baudax Bio, Inc.","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.523174+00:00","generated_at":"2026-06-17T06:32:40.901869+00:00","sec_items":["1.01","1.02","2.01","2.03","3.02","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Baudax Bio transfers ANJESO assets to Alkermes, terminates related agreements, amends credit facility","bullets":["Transferred patents, trademarks, equipment, data, and ANJESO NDA to Alkermes; no further payments due under terminated ANJESO agreements.","Amended credit agreement: lenders consented to asset sale, released liens on transferred assets, reduced minimum liquidity covenant to $2.5M.","Issued warrants to MAM Eagle Lender for 785,026 shares at $1.8951/share, exercisable for 10 years; registration rights granted.","Company will withdraw ANJESO NDA and transfer to Alkermes if requested; acquired regulatory approvals included in transfer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-090855","json":"https://secwatch.observer/filing/0001193125-23-090855.json","markdown":"https://secwatch.observer/filing/0001193125-23-090855.md","text":"https://secwatch.observer/filing/0001193125-23-090855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/d460062d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:32:40.901869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a3b6967b9222c51656bfb63096e70902568355e","claim":"Baudax Bio, Inc. amended credit facility with Wilmington Trust, National Association.","evidence_excerpt":"LLC, Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party and (ii) the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (the “Transfer Agreement”), each as described in greater detail in the Original 8-K.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Counterparty","value":"Wilmington Trust, National Association"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"d95b0595766b99486989fb3ad4f8ab59fb0fde5a","claim":"Baudax Bio, Inc. completed a disposition involving Alkermes Pharma Ireland Limited (closed 2023-03-29).","evidence_excerpt":"LLC, Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent and the lenders party and (ii) the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (the “Transfer Agreement”), each as described in greater detail in the Original 8-K.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Alkermes Pharma Ireland Limited"},{"label":"Closing","value":"2023-03-29"}],"fact_type":"ma_transaction"},{"claim_id":"490087bf0e6d9234447a7def932711eabcc3536b","claim":"Baudax Bio, Inc. amended Amendment No. 5 and Consent to Credit Agreement with Wilmington Trust, National Association, as agent, and the lenders party thereto (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023 (the “Closing Date”), Baudax Bio, Inc. (the “Company”) entered into that certain Amendment No. 5 and Consent to Credit Agreement (the “Amendment”) by and among the Company, Baudax Bio N.A. LLC (“Baudax LLC”), Baudax Bio Limited, Wilmington Trust, National Association, solely in its capacity as administrative and collateral agent (the “Agent”) and the lenders party thereto (the “Lenders”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Wilmington Trust, National Association, as agent, and the lenders party thereto"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"},{"claim_id":"6c85e81af380b3ca1f46060d4a16e83e7a49dea1","claim":"Baudax Bio, Inc. terminated ANJESO Agreements (PSA, ATLA, Manufacturing Agreement) with Alkermes Pharma Ireland Limited (effective 2023-03-29).","evidence_excerpt":"Alkermes Agreement On March 29, 2023, the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (“Alkermes”) (the “Transfer Agreement”). Under the terms of the Transfer Agreement, the Company transferred the rights to certain patents, trademarks, equipment, data and other rights related to ANJESO ® (the “Assets”) to Alkermes.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Alkermes Pharma Ireland Limited"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"},{"claim_id":"70cd4d5d57729f775ded51641422234ea0bcf7d6","claim":"Baudax Bio, Inc. entered into Asset Transfer Agreement with Alkermes Pharma Ireland Limited (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, the Company entered into an Asset Transfer Agreement with Alkermes Pharma Ireland Limited (“Alkermes”) (the “Transfer Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Alkermes Pharma Ireland Limited"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"},{"claim_id":"b2b954a726e4667cd7a4748035140188a2257fa1","claim":"Baudax Bio, Inc. entered into Registration Rights Agreement with MAM Eagle Lender, LLC (effective 2023-03-29).","evidence_excerpt":"the registration rights agreement by and between the Company and MAM Eagle Lender, LLC, entered into on March 29, 2023 (the “Registration Rights Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523090855/0001193125-23-090855-index.htm","confidence":0.8,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"MAM Eagle Lender, LLC"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}